Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT04285268 · WITHDRAWN

Trial details

NCT number: NCT04285268
Sponsor: Rutgers, The State University of New Jersey
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Start date: 2020-05-06
Primary completion: 2024-09-30
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.